Abstract:
Background: - Diabetes mellitus is an abnormal metabolic condition manifested by high
blood sugar levels resulting from defective insulin action or, secretion, or both. Liver disorder
is known to be one of the risk factors for diabetes and diabetics are known to be prone to both
liver and kidney disorders. But, the association between these diseases is not well studied.
Objective: The study was aimed to evaluate liver biomarkers and their associated factors
among T2D patients with CKD and T2D without CKD attending JMC from November 01,
2022 to January 20, 2023.
Materials and Methods: - An institutional -based comparative cross-sectional study design
was implemented at Jimma Medical Center from November 01, 2022 to January 20, 2023.
Consecutive sampling technique was implemented to gather the data. The data were entered
into EpiData version 4.6.0.6, exported to SPSS version 26 for analysis, and statistically tested
at a 95% Confidence level. The mean difference was tested using an independent t-test and
the relationship predictors and dependant variables were tested by using logistic regression.
Results: A Total of 142 of type 2 diabetes subjects were included in the study. Mean value of
alkaline phosphatase was higher in type2 with chronic kidney disease (115.27 ± 22.41 vs.
97.42 ± 29.57 P<0.001) but that of total bilirubin (0.86 ± 0.47 vs. 1.03 ± 0.48, p =0.028,) and
direct bilirubin (0 .16 ± 0.083 vs. 0.21 ± 0.09 p = 0.003), were lower among T2D patients with
CKD. T2D patients with chronic kidney disease were 2.2 times likelihood to have elevated
alkaline phosphatase levels than diabetics without chronic kidney disease (AOR =2.2 (1.09,
4.46) p= 0.028).T2D patients without chronic kidney disease were 2.8 and 5.1 times likelihood
to have elevated direct and total bilirubin than T2D with chronic kidney disease (AOR = 2.8
(1.29, 6.06) P=0.009 and AOR = 5.14(2.24, 11.56) P< 0.001) respectively.
Conclusion: The mean of alkaline phosphatase was significantly higher in type 2 diabetes
with chronic kidney disease than without chronic kidney disease. Whereas the mean of direct
and total bilirubin was lower in type 2 patients with chronic kidney disease.
Recommendation: stakeholders are recommended to consider liver biomarkers of type 2
patients with chronic kidney disease for early diagnosis, and prevention of liver disease.
